Is denosumab better than alendronate in the treatment of osteoporosis?

Nature Clinical Practice Rheumatology

Volumn 5, Issue 2, 2009, Pages 72-73

  Lewiecki, Michael E ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; ZOLEDRONIC ACID;

BONE DENSITY; BONE MASS; BONE TURNOVER; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FRACTURE REDUCTION; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; NOTE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 59849129260     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0981     Document Type: Note

References (7)

1. Bone HG et al. (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93: 2149-2157
2. Cummings SR et al. (2008) A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: Results from the FREEDOM trial [abstract]. J Bone Miner Res 23 (suppl): S80
3. McClung MR et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821-831
4. Lewiecki EM et al. (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 22: 1832-1841
5. Brown JP et al. (2008) Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res [doi:10.1359/JBMR.080910]
6. Gold DT et al. (2008) Preference and satisfaction with a 6-monthly subcutaneous injection versus a weekly tablet for treatment of low bone mass [abstract]. J Bone Miner Res 23 (suppl): S467
7. Kendler DL et al. (2008) Effects of denosumab vs alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate [abstract]. J Bone Miner Res 23 (suppl): S473